Horizons Ventures acts as the private investment arm for Mr Li Ka-shing, backing prominent technology companies and innovators.
Portfolio
7
companies
CellVoyant
CellVoyant is a biotechnology company developing artificial intelligence platforms to advance novel stem cell therapies.
Curio
Curio operates a subscription audio platform that provides curated spoken word journalism.
Fidel
Fidel provides an API that connects developers to major card networks for real-time payment data.
Kuato Studios
Kuato Studios develops educational games and virtual reality software for children.
Notpla
Notpla creates sustainable plant and seaweed packaging materials to replace single-use plastics.
Owlstone Medical
Owlstone Medical creates breath biopsy technology for non-invasive disease detection.
Patrick Zhang
Investor
Patrick is a general partner at Horizons Ventures, focusing on biotech investments. He also holds board observer roles across several life sciences companies, including HistoSonics and Chemify.
LinkedInVentura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.
"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
UB Forest Industry Green Growth Fund led the round to support manufacturing scale and North American expansion.
"We are thrilled to have secured this level of investment in such a competitive environment. This round not only validates our approach but also positions us to capitalise on the growing demand for truly plastic-free packaging solutions in global markets, especially as we develop our material’s possibilities."
Octopus Ventures led the seed financing, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, to commercialise live cell imaging technology.
"University spin-outs like CellVoyant are at the heart of the UK’s thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments."
The life sciences software provider raised the capital from Horizons Ventures and Sofinnova Partners to fund commercial growth.
"But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources."
The oversubscribed financing round will support the commercialisation of proprietary breath biopsy tests.
"We are thrilled to have the support of such highly respected investors as we strive to have a major impact on patient outcomes and the efficient delivery of healthcare resources and are very pleased to now welcome the experience and insight of Horizons’ Patrick Zhang to our Board."
